We are live on ! Find out more
JNP

Juniper Pharmaceuticals, Inc. Common Stock
JNP

Delisted

JNP was delisted on the 13th of August, 2018.

Back to rankings

Fund managers haven’t disclosed any holdings of JNP yet.

JNP Hedge Fund Activity: Q3 2018 in Review

0 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2018, worth a combined $0 — down 100% from $44.1M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of JNP and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $6.54M sold.

  • 0 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2018, down from 48 in Q2 2018.
  • Funds reported $0 of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 47 closed out, a net change of -47 holders.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Renaissance Technologies, an estimated $6.54M sold.

Based on aggregated 13F filings for Q3 2018.